Back to Search Start Over

Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project

Authors :
Cazzaniga, Marina Elena
Ciaccio, Antonio
Danesi, Romano
Duhoux, Francois P.
Girmenia, Corrado
Zaman, Kalhil
Lindman, Henrik
Luppi, Fabrizio
Mavroudis, Dimitrios
Paris, Ida
Olubukola, Ayodele
Samreen, Ahmed
Schem, Christian
Singer, Christian
Snegovoy, Anton
Source :
Frontiers in Oncology; 2023, p1-10, 10p
Publication Year :
2023

Abstract

The personalization of therapies in breast cancer has favoured the introduction of new molecular-targeted therapies into clinical practice. Among them, cyclindependent kinases 4 and 6 (CDK4/6) inhibitors have acquired increasing importance, with the approval in recent years of palbociclib, ribociclib, and abemaciclib in combination with endocrine therapy. Currently, no guidelines are available to monitor and manage potential long-term toxicities associated with the use of these drugs. A multidisciplinary panel of European oncologists, was supported by a pharmacologist, a hematologist, a hepatologist and a pulmonologist to discuss the management of long-term toxicities, based on the literature review and their clinical experience. The panel provided detailed roadmaps to manage long-term toxicities associated with the use of CDK4/6 inhibitors in clinical practice. Knowing the frequency and characteristics of the toxicity profile associated with each CDK4/6 inhibitor is important in the decision-making process to match the right drug to the right patient. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
2234943X
Database :
Complementary Index
Journal :
Frontiers in Oncology
Publication Type :
Academic Journal
Accession number :
173675856
Full Text :
https://doi.org/10.3389/fonc.2023.1247270